Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress toward developing a cytomegalovirus vaccine.

G S Marshall1, S A Plotkin

  • 1University of Louisville, Kentucky.

Infectious Disease Clinics of North America
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zika as still another argument for a new path to vaccine development.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2016
Same author

The Burden of Infant Meningococcal Disease in the United States.

Journal of the Pediatric Infectious Diseases Society·2013
Same author

Building on the success of the Expanded Programme on Immunization: enhancing the focus on disease prevention and control.

Vaccine·2011
Same author

WITHDRAWN: Letter to the Editor.

Vaccine·2011
Same author

Stress analysis by photoelastic method; two-dimensional principles and practice.

The New Zealand journal of science and technology. B. General section·2010
Same author

Respiration in High Flying: (United Services Section).

Proceedings of the Royal Society of Medicine·2009
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Cytomegalovirus (CMV) disease poses a significant public health threat. Research indicates that a CMV vaccine, potentially using molecular subunits, shows promise for preventing this widespread viral infection.

Area of Science:

  • Virology and Immunology
  • Vaccine Development

Background:

  • Cytomegalovirus (CMV) disease significantly impacts public health.
  • Existing data suggest CMV disease is a potential target for vaccine immunoprophylaxis.
  • Natural CMV infection offers some protection, serving as a model for vaccine efficacy.

Purpose of the Study:

  • To evaluate the potential of vaccine immunoprophylaxis against cytomegalovirus (CMV) disease.
  • To explore the safety and immunogenicity of a live attenuated CMV vaccine (Towne strain).
  • To investigate subunit vaccines that retain immunogenicity without viral nucleic acid.

Main Methods:

  • Clinical trials assessing the safety and immunogenicity of the live attenuated Towne CMV strain.
  • Research focused on identifying viral subunits with immunogenic properties.

Related Experiment Videos

  • Analysis of vaccine-induced protection mimicking natural infection.

    • Main Results:

    • The live attenuated CMV Towne strain has demonstrated safety and immunogenicity in clinical trials.
    • Protection conferred by the vaccine appears comparable to natural infection.
    • Promising results have emerged from research into subunit vaccines lacking viral nucleic acid.

    Conclusions:

    • Vaccine immunoprophylaxis holds significant promise for controlling cytomegalovirus (CMV) disease.
    • The Towne CMV vaccine is safe and elicits an immune response.
    • Subunit vaccine candidates are a promising area for future CMV vaccine development.